CMS proposes to expand coverage for Next Generation Sequencing tests for certain cancer patients

On Tuesday, October 29, CMS issued a "Proposed Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer" (Proposed Decision Memo) that would expand Medicare coverage of FDA-approved NGS lab tests for patients with ovarian or breast cancer that may be caused by hereditary factors, regardless of cancer stage. It also offers Medicare Administrative Contractors (MACs) greater discretion over coverage of NGS tests that are not FDA approved or cleared for certain patients with diagnoses other than breast and ovarian cancer.

Read More: CMS proposes to expand coverage for Next Generation Sequencing tests for certain cancer patients


Download PDF Share Back To Listing
Loading data